You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Non-squamous NSCLC

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non-squamous Non-small-cell Lung Cancer Trial in Hangzhou (Tusamitamab ravtansine+Sintilimab+Carboplatin or

Not yet recruiting
  • Non-squamous Non-small-cell Lung Cancer
  • Tusamitamab ravtansine+Sintilimab+Carboplatin or Cisplatin+Pemetrexed
  • +2 more
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
May 5, 2023

NSCLC Trial (Ivonescimab Injection, Pembrolizumab Injection)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Ivonescimab Injection
  • Pembrolizumab Injection
  • (no location specified)
Jun 9, 2023

Lung Cancer, Non Small Cell Lung Cancer, Adenocarcinoma of Lung Trial run by the National Cancer Institute (NCI) (LMB-100,

Active, not recruiting
  • Lung Cancer
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Oct 4, 2022

NSCLC Trial (SKB264, Pemetrexed, Carboplatin)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • (no location specified)
May 23, 2023

Non-Small Cell Carcinoma of Lung, TNM Stage 4 Trial in Philadelphia (Arm A, Arm B)

Recruiting
  • Non-Small Cell Carcinoma of Lung, TNM Stage 4
  • Arm A
  • Arm B
  • Philadelphia, Pennsylvania
    Fox Chase Cancer Center
Feb 8, 2022

Non-squamous Non-small-cell Lung Cancer, Brain Metastases Trial in Guangzhou (Camrelizumab, Pemetrexed, Carboplatin)

Active, not recruiting
  • Non-squamous Non-small-cell Lung Cancer
  • Brain Metastases
  • Guangzhou, Guangzhou, China
    Li-Kun Chen
Nov 13, 2022

NSCLC, NSCLC Stage IV, NSCLC Stage IIIB Trial (MYTX-011)

Not yet recruiting
  • NSCLC
  • +5 more
  • (no location specified)
Dec 7, 2022

NSCLC Trial (Bemcentinib, Pembrolizumab, Pemetrexed)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • (no location specified)
Jul 19, 2022

Squamous NSCLC, Non-Squamous NSCLC Trial (Durvalumab, Tremelimumab)

Withdrawn
  • Squamous Non-small Cell Lung Cancer
  • Non-Squamous Non-small Cell Lung Cancer
  • (no location specified)
Dec 17, 2021

Non Small Cell Lung Cancer, Immune Checkpoint Inhibitor, EGFR Exon 21 Mutation Trial in Peking (Pembrolizumab, pemetrexed,

Not yet recruiting
  • Non Small Cell Lung Cancer
  • +2 more
  • Peking, China
    Peking Union Medical College Hospital
Nov 16, 2023

Advanced Squamous Non Small Cell Lung Cancer Trial in Dallas (Afatinib + Prednisone)

Recruiting
  • Advanced Squamous Non Small Cell Lung Cancer
  • Afatinib + Prednisone
  • Dallas, Texas
    UT Southwestern Medical Center
Jun 28, 2022

Under Immunotherapy in Metastatic NSCLC: Sputum, Blood Samples

Recruiting
  • Non-squamous Lung Cancer
  • Metastatic Lung Cancer
  • Blood
  • +3 more
  • Tours, France
    University hospital
Nov 7, 2022

Squamous Cell NSCLC Trial in Hangzhou (Sintilimab, Carboplatin, Albumin-Bound Paclitaxel)

Not yet recruiting
  • Squamous Cell Non-small Cell Lung Cancer
  • Sintilimab
  • +2 more
  • Hangzhou, Zhejiang, China
    Second Affiliated Hospital, School of Medicine, Zhejiang Univers
Jun 19, 2022

EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC Trial in Worldwide (Atezolizumab, Bevacizumab, Carboplatin)

Active, not recruiting
  • EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC
  • Großhansdorf, Germany
  • +17 more
Jan 12, 2023

Advanced Non-Small Cell Squamous Lung Cancer, Radiotherapy, Immunotherapy Trial in Wuhan (CTV omitted or delineated)

Not yet recruiting
  • Advanced Non-Small Cell Squamous Lung Cancer
  • +2 more
  • CTV omitted or delineated
  • Wuhan, Hubei, China
    Hubei Cancer Hospital
Sep 7, 2023

NSCLC, Stage III Trial in Beijing (Tislelizumab, Pemetrexed (Nonsquamous NSCLC) or Paclitaxel/Nab-paclitaxel(Squamous NSCLC),

Recruiting
  • NSCLC, Stage III
  • Beijing, Beijing, China
    Beijing Tsinghua Chang Gung Hospital
Nov 4, 2022

NSCLC Trial (Durvalumab, Tremelimumab, Pemetrexed)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • (no location specified)
Aug 17, 2023

NSCLC Trial (AK119, AK112, Pemetrexed)

Not yet recruiting
  • NSCLC
  • (no location specified)
Nov 23, 2022

Metastatic NSCLC (NSCLC), Non-squamous NSCLC Trial (ABP 215, Bevacizumab, Paclitaxel)

Withdrawn
  • Metastatic Non-small Cell Lung Cancer (NSCLC)
  • Non-squamous NSCLC
  • ABP 215
  • +3 more
  • (no location specified)
May 19, 2021

Non Small Cell Lung Cancer Metastatic, Newly Diagnosed NSCLC, Non-Squamous Non-Small Cell Tumor of Lung Trial in United States

Not yet recruiting
  • Non Small Cell Lung Cancer Metastatic
  • +2 more
  • iNUDGE
  • Cherry Hill, New Jersey
  • +5 more
May 9, 2023

Advanced Squamous Non-Small Cell Lung Carcinoma Trial in Beijing, Tianjin, Kunming (TQB2450, Anlotinib HCl capsule, Tislelizumab

Not yet recruiting
  • Advanced Squamous Non-Small Cell Lung Carcinoma
  • Beijing, Beijing, China
  • +3 more
Feb 12, 2023

NSCLC, Metastatic Non Small Cell Lung Cancer, Stage IV NSCLC Trial in Duarte, Minneapolis (Fludarabine, Cyclophosphamide, CISH

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • +5 more
  • Duarte, California
  • +1 more
Dec 7, 2022

NSCLC Stage II, NSCLC, Stage IIIA, NSCLC Stage IIIB Trial in Heidelberg (Atezolizumab)

Recruiting
  • NSCLC Stage II
  • +2 more
  • Heidelberg, BaWü, Germany
    Thoraxklinik Heidelberg gGmbH
Apr 25, 2021

Carcinoma, Non-Small-Cell Lung Trial in Beijing (HLX10, an engineered anti-PD-1 antibody, HLX04, a bevacizumab biosimilar,

Recruiting
  • Carcinoma
  • Non-Small-Cell Lung
  • HLX10, an engineered anti-PD-1 antibody
  • +3 more
  • Beijing, Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences (CAMS)
Apr 29, 2022

Metastatic Breast Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Solid Tumor, Adult Trial (Patritumab deruxtecan)

Not yet recruiting
  • Metastatic Breast Cancer
  • +2 more
  • Patritumab deruxtecan
  • (no location specified)
May 9, 2023